Profiel
Daniel Blessing is the founder of HAYA Therapeutics SA. He held the title of Chief Technology Officer at the company, but is no longer active in that role.
Actieve functies van Daniel Blessing
| Bedrijven | Functie | Begin |
|---|---|---|
HAYA Therapeutics SA
 HAYA Therapeutics SA BiotechnologyHealth Technology HAYA Therapeutics SA is a Swiss precision medicines company that focuses on developing programmable therapeutics targeting regulatory RNAs derived from the dark genome to reprogram pathological cell states for a broad range of diseases, including cardiovascular disease and cancer. The company's discovery engine identifies novel targets and drug candidates with the potential for greater efficacy and safety than existing treatments. HAYA's lead therapeutic candidate is HTX-001, an antisense oligonucleotide targeting WISPER that is a heart-specific lncRNA known to be a fundamental regulator of pathological cardiac fibrosis in the context of heart failure. The company is headquartered at the Life Sciences Park Biopôle in Lausanne, CH, with laboratory facilities at JLABS @ San Diego. The company was founded by Samir Ounzain and Daniel Blessing, and Samir Ounzain has been the CEO since incorporation. | Oprichter | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 1 |
|---|---|
HAYA Therapeutics SA
HAYA Therapeutics SA BiotechnologyHealth Technology HAYA Therapeutics SA is a Swiss precision medicines company that focuses on developing programmable therapeutics targeting regulatory RNAs derived from the dark genome to reprogram pathological cell states for a broad range of diseases, including cardiovascular disease and cancer. The company's discovery engine identifies novel targets and drug candidates with the potential for greater efficacy and safety than existing treatments. HAYA's lead therapeutic candidate is HTX-001, an antisense oligonucleotide targeting WISPER that is a heart-specific lncRNA known to be a fundamental regulator of pathological cardiac fibrosis in the context of heart failure. The company is headquartered at the Life Sciences Park Biopôle in Lausanne, CH, with laboratory facilities at JLABS @ San Diego. The company was founded by Samir Ounzain and Daniel Blessing, and Samir Ounzain has been the CEO since incorporation. | Health Technology |
